Liver Cancer Therapeutics Market to 2018 – Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail


“The Report Liver Cancer Therapeutics Market to 2018 – Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

Leading business intelligence provider, GBI Research, has released its latest research report, entitled: “Liver Cancer Therapeutics Market to 2018 – Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail”. The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer therapeutics R&D pipeline. The report also gives in-depth analysis of the unmet needs, drivers and barriers that affect the markets in these countries. Additionally, it discusses the global pipeline for all the liver cancer molecules across various stages of development.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research found that the liver cancer therapeutics in the top seven markets (the US, the UK, Germany, France, Spain, Italy and Japan) was estimated at $374.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 21.7% from 2004. Growth was driven by an increase in the patient volume and the Annual Cost of Therapy (ACT) per patient, which increased due to the approval of Nexavar (sorafenib) in the US and Europe. The market is forecast to reach revenues of $644.3m by 2018, growing at a CAGR of 8.1% from 2011.

The current competition in the liver cancer market is weak, as Nexavar is the only drug approved for advanced Hepatocellular Carcinoma (HCC) with the exception of Miripla (miriplatin) in Japan. However, there are some molecules in Phase III development as first-line and second-line treatments which promise to influence the competitive landscape in the next two to three years. The anticipated launch of Eli Lilly’s ramucirumab (IMC-1121B), a monoclonal antibody in 2014; Celsion Corporation’s ThermoDox in 2014; and PrevOnco in 2015 will drive the market forward.

View Report At :http://www.marketresearchreports.biz/analysis/158133

Scope

  • Annualized market data for the liver cancer therapeutics market from 2004 to 2011 and forecast to 2018

  • Analysis of the liver cancer therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan

  • Market characterization of the liver cancer therapeutics market including market size, annual cost of therapy and treatment usage patterns

  • Key drivers and barriers that affect the market

  • Coverage of pipeline molecules in various Phases of drug development

  • Competitive benchmarking of leading companies including Bayer and Dainippon Sumitomo Pharma

  • Key M&A activities and licensing agreements that have taken place between 2008 and October 2012 in liver cancer therapeutics in the top seven markets

Reasons to buy

  • Align your product portfolio to the markets with high growth potential

  • Develop market-entry and market-expansion strategies by identifying the regions and market segments poised for strong growth

  • Create a more tailored country strategy through the understanding of key drivers and barriers of the liver cancer therapeutics market

  • Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies

  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/158133

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Liver Cancer Therapeutics Market to 2018 – Introduction 9

3 Liver Cancer Therapeutics Market to 2018 – Overview 10

3.1 Introduction 10

3.1.1 Benign Tumor 10

3.1.2 Primary Liver Cancer 10

3.1.3 Secondary Liver Cancer 10

3.2 Symptoms 11

3.3 Diagnosis 11

3.3.1 Laboratory Tests 11

3.3.2 Imaging Tests 11

3.3.3 Others 12

3.4 Treatment Options 12

3.4.1 Surgery 13

3.4.2 Non-surgical 13

3.4.3 General Treatment Algorithm 15

3.4.4 Treatment by Stage 16

3.4.5 New Technologies in Treatment 18

4 Liver Cancer Therapeutics Market to 2018 – Market Characterization and Forecasts 19

4.1 Revenue 19

4.2 Annual Cost of Therapy 22

4.3 Marketed Products 23

4.3.1 Nexavar 23

4.3.2 Miripla 25

4.4 Treatment Usage Pattern 27

4.4.1 Prevalence Population 28

4.4.2 Diagnosed Population 28

4.4.3 Prescription Population 28

4.5 Drivers and Barriers of Liver Cancer Therapeutics Market 28

4.5.1 Drivers 28

4.5.2 Barriers 29

5 Liver Cancer Therapeutics Market to 2018 – Geographical Landscape 30

5.1 US 30

5.1.1 Introduction 30

5.1.2 Revenue 30

5.1.3 Cost of Therapy 32

5.1.4 Treatment Usage Pattern 33

5.2 Top Five European Countries 34

5.2.1 Introduction 34

5.2.2 Revenue 34

5.2.3 Cost of Therapy 36

5.2.4 Treatment Usage Pattern 37

5.3 Japan 38

5.3.1 Introduction 38

5.3.2 Revenue 38

5.3.3 Cost of Therapy 39

5.3.4 Treatment Usage Pattern 40

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

banner